A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.

Key facts

Sponsor

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

Principal Investigator

Zhicheng Jing, M.D.

Guangdong Provincial People's Hospital

Intervention

IMC-003 and PAH background therapy(drug)

Enrollment

120 enrolled

Eligibility

18-75 years · All sexes

Timeline

2026 – 2027

Study locations (26)

• Xuanwu Hospital Capital Medical University, Beijing, Beijing Municipality, China
• The first hospital of Jilin University, Jilin, Changchun, China
• Fujian Medical University Union Hospita, Fuzhou, Fujian, China
• Xiamen Hospital of T.C.M., Xiamen, Fujian, China
• Gansu Provincial Hospital, Lanzhou, Gansu, China
• Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
• The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
• Fuwai Center China Cardiovascular Hospital, Zhengzhou, Henan, China
• The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
• Wuhan Asia Heart Hospital, Wuhan, Hubei, China
• Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
• The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
• Xuzhou Central Hospital, Xuzhou, Jiangsu, China
• The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
• General Hospital of the Northern Theater Command, Shenyang, Liaoning, China
• +11 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07563322
  Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension
  Vanderbilt University Medical Center
• ACTIVE NOT RECRUITINGNANCT07391228
  Cognitive Alterations in Pulmonary Arterial Hypertension (PAH)
  Alessandra Gorini
• RECRUITINGNANCT06871293
  Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19
  Fundación Cardioinfantil Instituto de Cardiología
• RECRUITINGNANCT06911632
  Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
  Tempus AI
• ACTIVE NOT RECRUITINGPHASE3NCT06274801
  Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
  GB002, Inc.
• RECRUITINGPHASE2NCT05937854
  Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
  VA Office of Research and Development
• RECRUITINGNCT06291389
  Intraoperative Peak Airway Pressure Changes on Postoperative Pulmonary Function After Muscle Plication
  Al-Azhar University
• ACTIVE NOT RECRUITINGNANCT07253363
  Circulating Activin-A and FSTL3 in Precapillary Pulmonary Hypertension
  Assistance Publique - Hôpitaux de Paris

See all trials for Pulmonary arterial hypertension →